Andrew McConaghie

Executive Summary CEO Chris Cargill talks to Scrip about Sosei Heptares' new identity as Nxera, the ups and downs of being big pharma's go-to small-molecule drug hunter and its move into commercialization in Japan.

Executive Summary Business development leaders from AstraZeneca and Novartis and a biotech CEO get frank about what they want from the other

Executive Summary The $100m upfront deal help AZ to fill out its cardiovascular, renal and metabolism portfolio, now joining Lilly in seeking to develop an oral Lp(a)-targeting therapy.

Executive Summary Purespring has just raised $105m from an investor syndicate who are betting it can develop the first gene therapy for kidney disease and learn from setbacks experienced in the space.

Executive Summary Arexvy has become the first RSV vaccine to show it can provide protection over three years – but that might mean lower market uptake than originally expected.

The payout will bring GSK closer to resolving lawsuits which have occupied it for years – though investors are now likely to focus on new product growth concerns at the UK firm.

Executive Summary The Swiss company is aiming to regain its innovator status and expand its offering across all breast cancer settings.

Executive Summary Approval based on the Phase II results could come in early 2025, with a Phase III study already underway.

The combination results with Tecentriq bolster the case for Jazz's drug, but it will still face competition from Amgen's Imdeltra and others in the hard-to-treat cancer.

The company's share price has rocketed after becoming the first to show RNA editing works in humans, providing new competition for gene-editing firms.